# ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

> **NCT01663402** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 18924 (actual)

## Conditions studied

- Atherosclerotic Cardiovascular Disease

## Interventions

- **DRUG:** Alirocumab
- **DRUG:** Placebo
- **DRUG:** LMT

## Key facts

- **NCT ID:** NCT01663402
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2018-01-23
- **Final completion:** 2018-01-23
- **Target enrollment:** 18924 (ACTUAL)
- **Last updated:** 2019-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01663402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01663402, "ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01663402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*